ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Hepatocellular Carcinoma Monoclonal Antibody Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-25Y18663
Home | Market Reports | Health| Health Conditions| Cancer
Global Hepatocellular Carcinoma Monoclonal Antibody Market Research Report 2025
BUY CHAPTERS

Global Hepatocellular Carcinoma Monoclonal Antibody Market Research Report 2025

Code: QYRE-Auto-25Y18663
Report
January 2025
Pages:84
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Roche Holding AG
Bristol-Myers Squibb Co
Merck& Co. Inc
Astrazeneca plc
BeiGene Ltd
Innovent Biologics, Inc.
Jiangsu Hengrui Pharmaceutical Group Co. Ltd

Hepatocellular Carcinoma Monoclonal Antibody Market Size

The global market for Hepatocellular Carcinoma Monoclonal Antibody was valued at US$ 1499 million in the year 2024 and is projected to reach a revised size of US$ 4513 million by 2031, growing at a CAGR of 17.3% during the forecast period.

Hepatocellular Carcinoma Monoclonal Antibody Market

Hepatocellular Carcinoma Monoclonal Antibody Market

Hepatocellular carcinoma monoclonal antibodies are a class of lab-made proteins that target specific molecular targets of hepatocellular carcinoma, such as tumor cell surface antigens or growth factor receptors, and they are able to recognize and bind these targets with a high degree of specificity to play a role in the treatment of hepatocellular carcinoma by activating the immune system or directly inhibiting tumor growth and angiogenesis.
North American market for Hepatocellular Carcinoma Monoclonal Antibody is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Hepatocellular Carcinoma Monoclonal Antibody is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Hepatocellular Carcinoma Monoclonal Antibody include Roche Holding AG, Bristol Myers Squibb Co., Merck & Co., Inc., AstraZeneca PLC, BeiGene, Ltd, Jiangsu Hengrui Pharmaceutical Group Co. Ltd, Innovent Biologics, Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Hepatocellular Carcinoma Monoclonal Antibody, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatocellular Carcinoma Monoclonal Antibody.
The Hepatocellular Carcinoma Monoclonal Antibody market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hepatocellular Carcinoma Monoclonal Antibody market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hepatocellular Carcinoma Monoclonal Antibody manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Hepatocellular Carcinoma Monoclonal Antibody Market Report

Report Metric Details
Report Name Hepatocellular Carcinoma Monoclonal Antibody Market
Accounted market size in year US$ 1499 million
Forecasted market size in 2031 US$ 4513 million
CAGR 17.3%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • 10 mg/mL
  • 25 mg/mL
  • 50 mg/mL
Segment by Application
  • Hospital
  • Clinic
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Roche Holding AG, Bristol Myers Squibb Co., Merck & Co., Inc., AstraZeneca PLC, BeiGene, Ltd, Jiangsu Hengrui Pharmaceutical Group Co. Ltd, Innovent Biologics, Inc
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Hepatocellular Carcinoma Monoclonal Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Hepatocellular Carcinoma Monoclonal Antibody in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Hepatocellular Carcinoma Monoclonal Antibody Market growing?

Ans: The Hepatocellular Carcinoma Monoclonal Antibody Market witnessing a CAGR of 17.3% during the forecast period 2025-2031.

What is the Hepatocellular Carcinoma Monoclonal Antibody Market size in 2031?

Ans: The Hepatocellular Carcinoma Monoclonal Antibody Market size in 2031 will be US$ 4513 million.

Who are the main players in the Hepatocellular Carcinoma Monoclonal Antibody Market report?

Ans: The main players in the Hepatocellular Carcinoma Monoclonal Antibody Market are Roche Holding AG, Bristol Myers Squibb Co., Merck & Co., Inc., AstraZeneca PLC, BeiGene, Ltd, Jiangsu Hengrui Pharmaceutical Group Co. Ltd, Innovent Biologics, Inc

What are the Application segmentation covered in the Hepatocellular Carcinoma Monoclonal Antibody Market report?

Ans: The Applications covered in the Hepatocellular Carcinoma Monoclonal Antibody Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Hepatocellular Carcinoma Monoclonal Antibody Market report?

Ans: The Types covered in the Hepatocellular Carcinoma Monoclonal Antibody Market report are 10 mg/mL, 25 mg/mL, 50 mg/mL

Recommended Reports

Liver Disease Therapeutics

Monoclonal Antibody Markets

Targeted & Antibody Therapy

1 Hepatocellular Carcinoma Monoclonal Antibody Market Overview
1.1 Product Definition
1.2 Hepatocellular Carcinoma Monoclonal Antibody by Type
1.2.1 Global Hepatocellular Carcinoma Monoclonal Antibody Market Value Comparison by Type (2024 VS 2031)
1.2.2 10 mg/mL
1.2.3 25 mg/mL
1.2.4 50 mg/mL
1.3 Hepatocellular Carcinoma Monoclonal Antibody by Application
1.3.1 Global Hepatocellular Carcinoma Monoclonal Antibody Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Hepatocellular Carcinoma Monoclonal Antibody Market Size Estimates and Forecasts
1.4.1 Global Hepatocellular Carcinoma Monoclonal Antibody Revenue 2020-2031
1.4.2 Global Hepatocellular Carcinoma Monoclonal Antibody Sales 2020-2031
1.4.3 Global Hepatocellular Carcinoma Monoclonal Antibody Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Hepatocellular Carcinoma Monoclonal Antibody Market Competition by Manufacturers
2.1 Global Hepatocellular Carcinoma Monoclonal Antibody Sales Market Share by Manufacturers (2020-2025)
2.2 Global Hepatocellular Carcinoma Monoclonal Antibody Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Hepatocellular Carcinoma Monoclonal Antibody Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Hepatocellular Carcinoma Monoclonal Antibody, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Hepatocellular Carcinoma Monoclonal Antibody, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Hepatocellular Carcinoma Monoclonal Antibody, Product Type & Application
2.7 Global Key Manufacturers of Hepatocellular Carcinoma Monoclonal Antibody, Date of Enter into This Industry
2.8 Global Hepatocellular Carcinoma Monoclonal Antibody Market Competitive Situation and Trends
2.8.1 Global Hepatocellular Carcinoma Monoclonal Antibody Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Hepatocellular Carcinoma Monoclonal Antibody Players Market Share by Revenue
2.8.3 Global Hepatocellular Carcinoma Monoclonal Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Hepatocellular Carcinoma Monoclonal Antibody Market Scenario by Region
3.1 Global Hepatocellular Carcinoma Monoclonal Antibody Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Hepatocellular Carcinoma Monoclonal Antibody Sales by Region: 2020-2031
3.2.1 Global Hepatocellular Carcinoma Monoclonal Antibody Sales by Region: 2020-2025
3.2.2 Global Hepatocellular Carcinoma Monoclonal Antibody Sales by Region: 2026-2031
3.3 Global Hepatocellular Carcinoma Monoclonal Antibody Revenue by Region: 2020-2031
3.3.1 Global Hepatocellular Carcinoma Monoclonal Antibody Revenue by Region: 2020-2025
3.3.2 Global Hepatocellular Carcinoma Monoclonal Antibody Revenue by Region: 2026-2031
3.4 North America Hepatocellular Carcinoma Monoclonal Antibody Market Facts & Figures by Country
3.4.1 North America Hepatocellular Carcinoma Monoclonal Antibody Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Hepatocellular Carcinoma Monoclonal Antibody Sales by Country (2020-2031)
3.4.3 North America Hepatocellular Carcinoma Monoclonal Antibody Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Hepatocellular Carcinoma Monoclonal Antibody Market Facts & Figures by Country
3.5.1 Europe Hepatocellular Carcinoma Monoclonal Antibody Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Hepatocellular Carcinoma Monoclonal Antibody Sales by Country (2020-2031)
3.5.3 Europe Hepatocellular Carcinoma Monoclonal Antibody Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hepatocellular Carcinoma Monoclonal Antibody Market Facts & Figures by Region
3.6.1 Asia Pacific Hepatocellular Carcinoma Monoclonal Antibody Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Hepatocellular Carcinoma Monoclonal Antibody Sales by Region (2020-2031)
3.6.3 Asia Pacific Hepatocellular Carcinoma Monoclonal Antibody Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Hepatocellular Carcinoma Monoclonal Antibody Market Facts & Figures by Country
3.7.1 Latin America Hepatocellular Carcinoma Monoclonal Antibody Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Hepatocellular Carcinoma Monoclonal Antibody Sales by Country (2020-2031)
3.7.3 Latin America Hepatocellular Carcinoma Monoclonal Antibody Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Hepatocellular Carcinoma Monoclonal Antibody Market Facts & Figures by Country
3.8.1 Middle East and Africa Hepatocellular Carcinoma Monoclonal Antibody Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Hepatocellular Carcinoma Monoclonal Antibody Sales by Country (2020-2031)
3.8.3 Middle East and Africa Hepatocellular Carcinoma Monoclonal Antibody Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Hepatocellular Carcinoma Monoclonal Antibody Sales by Type (2020-2031)
4.1.1 Global Hepatocellular Carcinoma Monoclonal Antibody Sales by Type (2020-2025)
4.1.2 Global Hepatocellular Carcinoma Monoclonal Antibody Sales by Type (2026-2031)
4.1.3 Global Hepatocellular Carcinoma Monoclonal Antibody Sales Market Share by Type (2020-2031)
4.2 Global Hepatocellular Carcinoma Monoclonal Antibody Revenue by Type (2020-2031)
4.2.1 Global Hepatocellular Carcinoma Monoclonal Antibody Revenue by Type (2020-2025)
4.2.2 Global Hepatocellular Carcinoma Monoclonal Antibody Revenue by Type (2026-2031)
4.2.3 Global Hepatocellular Carcinoma Monoclonal Antibody Revenue Market Share by Type (2020-2031)
4.3 Global Hepatocellular Carcinoma Monoclonal Antibody Price by Type (2020-2031)
5 Segment by Application
5.1 Global Hepatocellular Carcinoma Monoclonal Antibody Sales by Application (2020-2031)
5.1.1 Global Hepatocellular Carcinoma Monoclonal Antibody Sales by Application (2020-2025)
5.1.2 Global Hepatocellular Carcinoma Monoclonal Antibody Sales by Application (2026-2031)
5.1.3 Global Hepatocellular Carcinoma Monoclonal Antibody Sales Market Share by Application (2020-2031)
5.2 Global Hepatocellular Carcinoma Monoclonal Antibody Revenue by Application (2020-2031)
5.2.1 Global Hepatocellular Carcinoma Monoclonal Antibody Revenue by Application (2020-2025)
5.2.2 Global Hepatocellular Carcinoma Monoclonal Antibody Revenue by Application (2026-2031)
5.2.3 Global Hepatocellular Carcinoma Monoclonal Antibody Revenue Market Share by Application (2020-2031)
5.3 Global Hepatocellular Carcinoma Monoclonal Antibody Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Roche Holding AG
6.1.1 Roche Holding AG Company Information
6.1.2 Roche Holding AG Description and Business Overview
6.1.3 Roche Holding AG Hepatocellular Carcinoma Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Roche Holding AG Hepatocellular Carcinoma Monoclonal Antibody Product Portfolio
6.1.5 Roche Holding AG Recent Developments/Updates
6.2 Bristol Myers Squibb Co.
6.2.1 Bristol Myers Squibb Co. Company Information
6.2.2 Bristol Myers Squibb Co. Description and Business Overview
6.2.3 Bristol Myers Squibb Co. Hepatocellular Carcinoma Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Bristol Myers Squibb Co. Hepatocellular Carcinoma Monoclonal Antibody Product Portfolio
6.2.5 Bristol Myers Squibb Co. Recent Developments/Updates
6.3 Merck & Co., Inc.
6.3.1 Merck & Co., Inc. Company Information
6.3.2 Merck & Co., Inc. Description and Business Overview
6.3.3 Merck & Co., Inc. Hepatocellular Carcinoma Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Merck & Co., Inc. Hepatocellular Carcinoma Monoclonal Antibody Product Portfolio
6.3.5 Merck & Co., Inc. Recent Developments/Updates
6.4 AstraZeneca PLC
6.4.1 AstraZeneca PLC Company Information
6.4.2 AstraZeneca PLC Description and Business Overview
6.4.3 AstraZeneca PLC Hepatocellular Carcinoma Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)
6.4.4 AstraZeneca PLC Hepatocellular Carcinoma Monoclonal Antibody Product Portfolio
6.4.5 AstraZeneca PLC Recent Developments/Updates
6.5 BeiGene, Ltd
6.5.1 BeiGene, Ltd Company Information
6.5.2 BeiGene, Ltd Description and Business Overview
6.5.3 BeiGene, Ltd Hepatocellular Carcinoma Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)
6.5.4 BeiGene, Ltd Hepatocellular Carcinoma Monoclonal Antibody Product Portfolio
6.5.5 BeiGene, Ltd Recent Developments/Updates
6.6 Jiangsu Hengrui Pharmaceutical Group Co. Ltd
6.6.1 Jiangsu Hengrui Pharmaceutical Group Co. Ltd Company Information
6.6.2 Jiangsu Hengrui Pharmaceutical Group Co. Ltd Description and Business Overview
6.6.3 Jiangsu Hengrui Pharmaceutical Group Co. Ltd Hepatocellular Carcinoma Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Jiangsu Hengrui Pharmaceutical Group Co. Ltd Hepatocellular Carcinoma Monoclonal Antibody Product Portfolio
6.6.5 Jiangsu Hengrui Pharmaceutical Group Co. Ltd Recent Developments/Updates
6.7 Innovent Biologics, Inc
6.7.1 Innovent Biologics, Inc Company Information
6.7.2 Innovent Biologics, Inc Description and Business Overview
6.7.3 Innovent Biologics, Inc Hepatocellular Carcinoma Monoclonal Antibody Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Innovent Biologics, Inc Hepatocellular Carcinoma Monoclonal Antibody Product Portfolio
6.7.5 Innovent Biologics, Inc Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hepatocellular Carcinoma Monoclonal Antibody Industry Chain Analysis
7.2 Hepatocellular Carcinoma Monoclonal Antibody Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hepatocellular Carcinoma Monoclonal Antibody Production Mode & Process Analysis
7.4 Hepatocellular Carcinoma Monoclonal Antibody Sales and Marketing
7.4.1 Hepatocellular Carcinoma Monoclonal Antibody Sales Channels
7.4.2 Hepatocellular Carcinoma Monoclonal Antibody Distributors
7.5 Hepatocellular Carcinoma Monoclonal Antibody Customer Analysis
8 Hepatocellular Carcinoma Monoclonal Antibody Market Dynamics
8.1 Hepatocellular Carcinoma Monoclonal Antibody Industry Trends
8.2 Hepatocellular Carcinoma Monoclonal Antibody Market Drivers
8.3 Hepatocellular Carcinoma Monoclonal Antibody Market Challenges
8.4 Hepatocellular Carcinoma Monoclonal Antibody Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Roche Holding AG
Bristol-Myers Squibb Co
Merck& Co. Inc
Astrazeneca plc
BeiGene Ltd
Innovent Biologics, Inc.
Jiangsu Hengrui Pharmaceutical Group Co. Ltd
List of Tables
 Table 1. Global Hepatocellular Carcinoma Monoclonal Antibody Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Hepatocellular Carcinoma Monoclonal Antibody Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Hepatocellular Carcinoma Monoclonal Antibody Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Hepatocellular Carcinoma Monoclonal Antibody Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Hepatocellular Carcinoma Monoclonal Antibody Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Hepatocellular Carcinoma Monoclonal Antibody Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Hepatocellular Carcinoma Monoclonal Antibody Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Hepatocellular Carcinoma Monoclonal Antibody Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Hepatocellular Carcinoma Monoclonal Antibody, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Hepatocellular Carcinoma Monoclonal Antibody, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Hepatocellular Carcinoma Monoclonal Antibody, Product Type & Application
 Table 12. Global Key Manufacturers of Hepatocellular Carcinoma Monoclonal Antibody, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Hepatocellular Carcinoma Monoclonal Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatocellular Carcinoma Monoclonal Antibody as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Hepatocellular Carcinoma Monoclonal Antibody Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Hepatocellular Carcinoma Monoclonal Antibody Sales by Region (2020-2025) & (K Units)
 Table 18. Global Hepatocellular Carcinoma Monoclonal Antibody Sales Market Share by Region (2020-2025)
 Table 19. Global Hepatocellular Carcinoma Monoclonal Antibody Sales by Region (2026-2031) & (K Units)
 Table 20. Global Hepatocellular Carcinoma Monoclonal Antibody Sales Market Share by Region (2026-2031)
 Table 21. Global Hepatocellular Carcinoma Monoclonal Antibody Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Hepatocellular Carcinoma Monoclonal Antibody Revenue Market Share by Region (2020-2025)
 Table 23. Global Hepatocellular Carcinoma Monoclonal Antibody Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Hepatocellular Carcinoma Monoclonal Antibody Revenue Market Share by Region (2026-2031)
 Table 25. North America Hepatocellular Carcinoma Monoclonal Antibody Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Hepatocellular Carcinoma Monoclonal Antibody Sales by Country (2020-2025) & (K Units)
 Table 27. North America Hepatocellular Carcinoma Monoclonal Antibody Sales by Country (2026-2031) & (K Units)
 Table 28. North America Hepatocellular Carcinoma Monoclonal Antibody Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Hepatocellular Carcinoma Monoclonal Antibody Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Hepatocellular Carcinoma Monoclonal Antibody Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Hepatocellular Carcinoma Monoclonal Antibody Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Hepatocellular Carcinoma Monoclonal Antibody Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Hepatocellular Carcinoma Monoclonal Antibody Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Hepatocellular Carcinoma Monoclonal Antibody Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Hepatocellular Carcinoma Monoclonal Antibody Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Hepatocellular Carcinoma Monoclonal Antibody Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Hepatocellular Carcinoma Monoclonal Antibody Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Hepatocellular Carcinoma Monoclonal Antibody Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Hepatocellular Carcinoma Monoclonal Antibody Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Hepatocellular Carcinoma Monoclonal Antibody Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Hepatocellular Carcinoma Monoclonal Antibody Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Hepatocellular Carcinoma Monoclonal Antibody Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Hepatocellular Carcinoma Monoclonal Antibody Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Hepatocellular Carcinoma Monoclonal Antibody Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Hepatocellular Carcinoma Monoclonal Antibody Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Hepatocellular Carcinoma Monoclonal Antibody Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Hepatocellular Carcinoma Monoclonal Antibody Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Hepatocellular Carcinoma Monoclonal Antibody Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Hepatocellular Carcinoma Monoclonal Antibody Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Hepatocellular Carcinoma Monoclonal Antibody Sales (K Units) by Type (2020-2025)
 Table 51. Global Hepatocellular Carcinoma Monoclonal Antibody Sales (K Units) by Type (2026-2031)
 Table 52. Global Hepatocellular Carcinoma Monoclonal Antibody Sales Market Share by Type (2020-2025)
 Table 53. Global Hepatocellular Carcinoma Monoclonal Antibody Sales Market Share by Type (2026-2031)
 Table 54. Global Hepatocellular Carcinoma Monoclonal Antibody Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Hepatocellular Carcinoma Monoclonal Antibody Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Hepatocellular Carcinoma Monoclonal Antibody Revenue Market Share by Type (2020-2025)
 Table 57. Global Hepatocellular Carcinoma Monoclonal Antibody Revenue Market Share by Type (2026-2031)
 Table 58. Global Hepatocellular Carcinoma Monoclonal Antibody Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Hepatocellular Carcinoma Monoclonal Antibody Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Hepatocellular Carcinoma Monoclonal Antibody Sales (K Units) by Application (2020-2025)
 Table 61. Global Hepatocellular Carcinoma Monoclonal Antibody Sales (K Units) by Application (2026-2031)
 Table 62. Global Hepatocellular Carcinoma Monoclonal Antibody Sales Market Share by Application (2020-2025)
 Table 63. Global Hepatocellular Carcinoma Monoclonal Antibody Sales Market Share by Application (2026-2031)
 Table 64. Global Hepatocellular Carcinoma Monoclonal Antibody Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Hepatocellular Carcinoma Monoclonal Antibody Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Hepatocellular Carcinoma Monoclonal Antibody Revenue Market Share by Application (2020-2025)
 Table 67. Global Hepatocellular Carcinoma Monoclonal Antibody Revenue Market Share by Application (2026-2031)
 Table 68. Global Hepatocellular Carcinoma Monoclonal Antibody Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Hepatocellular Carcinoma Monoclonal Antibody Price (US$/Unit) by Application (2026-2031)
 Table 70. Roche Holding AG Company Information
 Table 71. Roche Holding AG Description and Business Overview
 Table 72. Roche Holding AG Hepatocellular Carcinoma Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Roche Holding AG Hepatocellular Carcinoma Monoclonal Antibody Product
 Table 74. Roche Holding AG Recent Developments/Updates
 Table 75. Bristol Myers Squibb Co. Company Information
 Table 76. Bristol Myers Squibb Co. Description and Business Overview
 Table 77. Bristol Myers Squibb Co. Hepatocellular Carcinoma Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Bristol Myers Squibb Co. Hepatocellular Carcinoma Monoclonal Antibody Product
 Table 79. Bristol Myers Squibb Co. Recent Developments/Updates
 Table 80. Merck & Co., Inc. Company Information
 Table 81. Merck & Co., Inc. Description and Business Overview
 Table 82. Merck & Co., Inc. Hepatocellular Carcinoma Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Merck & Co., Inc. Hepatocellular Carcinoma Monoclonal Antibody Product
 Table 84. Merck & Co., Inc. Recent Developments/Updates
 Table 85. AstraZeneca PLC Company Information
 Table 86. AstraZeneca PLC Description and Business Overview
 Table 87. AstraZeneca PLC Hepatocellular Carcinoma Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. AstraZeneca PLC Hepatocellular Carcinoma Monoclonal Antibody Product
 Table 89. AstraZeneca PLC Recent Developments/Updates
 Table 90. BeiGene, Ltd Company Information
 Table 91. BeiGene, Ltd Description and Business Overview
 Table 92. BeiGene, Ltd Hepatocellular Carcinoma Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. BeiGene, Ltd Hepatocellular Carcinoma Monoclonal Antibody Product
 Table 94. BeiGene, Ltd Recent Developments/Updates
 Table 95. Jiangsu Hengrui Pharmaceutical Group Co. Ltd Company Information
 Table 96. Jiangsu Hengrui Pharmaceutical Group Co. Ltd Description and Business Overview
 Table 97. Jiangsu Hengrui Pharmaceutical Group Co. Ltd Hepatocellular Carcinoma Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Jiangsu Hengrui Pharmaceutical Group Co. Ltd Hepatocellular Carcinoma Monoclonal Antibody Product
 Table 99. Jiangsu Hengrui Pharmaceutical Group Co. Ltd Recent Developments/Updates
 Table 100. Innovent Biologics, Inc Company Information
 Table 101. Innovent Biologics, Inc Description and Business Overview
 Table 102. Innovent Biologics, Inc Hepatocellular Carcinoma Monoclonal Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Innovent Biologics, Inc Hepatocellular Carcinoma Monoclonal Antibody Product
 Table 104. Innovent Biologics, Inc Recent Developments/Updates
 Table 105. Key Raw Materials Lists
 Table 106. Raw Materials Key Suppliers Lists
 Table 107. Hepatocellular Carcinoma Monoclonal Antibody Distributors List
 Table 108. Hepatocellular Carcinoma Monoclonal Antibody Customers List
 Table 109. Hepatocellular Carcinoma Monoclonal Antibody Market Trends
 Table 110. Hepatocellular Carcinoma Monoclonal Antibody Market Drivers
 Table 111. Hepatocellular Carcinoma Monoclonal Antibody Market Challenges
 Table 112. Hepatocellular Carcinoma Monoclonal Antibody Market Restraints
 Table 113. Research Programs/Design for This Report
 Table 114. Key Data Information from Secondary Sources
 Table 115. Key Data Information from Primary Sources
 Table 116. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Hepatocellular Carcinoma Monoclonal Antibody
 Figure 2. Global Hepatocellular Carcinoma Monoclonal Antibody Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Hepatocellular Carcinoma Monoclonal Antibody Market Share by Type: 2024 & 2031
 Figure 4. 10 mg/mL Product Picture
 Figure 5. 25 mg/mL Product Picture
 Figure 6. 50 mg/mL Product Picture
 Figure 7. Global Hepatocellular Carcinoma Monoclonal Antibody Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Hepatocellular Carcinoma Monoclonal Antibody Market Share by Application: 2024 & 2031
 Figure 9. Hospital
 Figure 10. Clinic
 Figure 11. Others
 Figure 12. Global Hepatocellular Carcinoma Monoclonal Antibody Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Hepatocellular Carcinoma Monoclonal Antibody Market Size (2020-2031) & (US$ Million)
 Figure 14. Global Hepatocellular Carcinoma Monoclonal Antibody Sales (2020-2031) & (K Units)
 Figure 15. Global Hepatocellular Carcinoma Monoclonal Antibody Average Price (US$/Unit) & (2020-2031)
 Figure 16. Hepatocellular Carcinoma Monoclonal Antibody Report Years Considered
 Figure 17. Hepatocellular Carcinoma Monoclonal Antibody Sales Share by Manufacturers in 2024
 Figure 18. Global Hepatocellular Carcinoma Monoclonal Antibody Revenue Share by Manufacturers in 2024
 Figure 19. Global 5 and 10 Largest Hepatocellular Carcinoma Monoclonal Antibody Players: Market Share by Revenue in Hepatocellular Carcinoma Monoclonal Antibody in 2024
 Figure 20. Hepatocellular Carcinoma Monoclonal Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 21. Global Hepatocellular Carcinoma Monoclonal Antibody Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 22. North America Hepatocellular Carcinoma Monoclonal Antibody Sales Market Share by Country (2020-2031)
 Figure 23. North America Hepatocellular Carcinoma Monoclonal Antibody Revenue Market Share by Country (2020-2031)
 Figure 24. United States Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Canada Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Europe Hepatocellular Carcinoma Monoclonal Antibody Sales Market Share by Country (2020-2031)
 Figure 27. Europe Hepatocellular Carcinoma Monoclonal Antibody Revenue Market Share by Country (2020-2031)
 Figure 28. Germany Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. France Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. U.K. Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Italy Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Russia Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific Hepatocellular Carcinoma Monoclonal Antibody Sales Market Share by Region (2020-2031)
 Figure 34. Asia Pacific Hepatocellular Carcinoma Monoclonal Antibody Revenue Market Share by Region (2020-2031)
 Figure 35. China Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Japan Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. South Korea Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. India Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Australia Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. China Taiwan Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Southeast Asia Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Latin America Hepatocellular Carcinoma Monoclonal Antibody Sales Market Share by Country (2020-2031)
 Figure 43. Latin America Hepatocellular Carcinoma Monoclonal Antibody Revenue Market Share by Country (2020-2031)
 Figure 44. Mexico Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Brazil Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Argentina Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Colombia Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Hepatocellular Carcinoma Monoclonal Antibody Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Hepatocellular Carcinoma Monoclonal Antibody Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Hepatocellular Carcinoma Monoclonal Antibody Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Hepatocellular Carcinoma Monoclonal Antibody by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Hepatocellular Carcinoma Monoclonal Antibody by Type (2020-2031)
 Figure 55. Global Hepatocellular Carcinoma Monoclonal Antibody Price (US$/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Hepatocellular Carcinoma Monoclonal Antibody by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Hepatocellular Carcinoma Monoclonal Antibody by Application (2020-2031)
 Figure 58. Global Hepatocellular Carcinoma Monoclonal Antibody Price (US$/Unit) by Application (2020-2031)
 Figure 59. Hepatocellular Carcinoma Monoclonal Antibody Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Global Monoclonal Antibody for Gastric Cancer Market Research Report 2024
Global Monoclonal Antibody Drugs for Cancer Market Research Report 2024
Global Therapeutic Monoclonal Antibodies Market Research Report 2024
Global Therapeutic Monoclonal Antibodies Drug Market Research Report 2024
Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Insights Forecast to 2030
Monoclonal Antibody Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Monoclonal Antibody Biologics and Biosimilars Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Monoclonal Antibody VEGF Inhibitors Market Research Report 2024
Global Conjugated Monoclonal Antibodies Market Research Report 2024
Biologics Monoclonal Antibodies Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global HCC Hepatocellular Carcinoma Biomarker Market Research Report 2024
Global Hepatocyte Growth Factor HGF Antibody Market Research Report 2024
Global Small Molecule Targeted Cancer Therapy Market Research Report 2025
Global HCC Biomarker Market Research Report 2024
Global Monoclonal Antibodies for Non small Cell Lung Cancer Market Research Report 2025
Global Anti CD20 Monoclonal Antibodies Market Research Report 2024
Global HER2 Antibody Market Research Report 2025
Global Myoglobin Monoclonal Antibody Market Research Report 2024
Global Ubiquitin Monoclonal Antibody Market Research Report 2024
Global Fibronectin Monoclonal Antibody Market Research Report 2024

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5L19798
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28I6901
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22R9736
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29A2598
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions